SVNS
BADSolvonis Therapeutics Announces Heavily Discounted Equity Raise
The biopharmaceutical company has announced a heavily discounted equity raise, which is a negative sign indicating potential financial challenges.
Solvonis Therapeutics
0.2800GBX
-3.45%
Market Cap
17.93M
Volume
1,000k
1% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
1.52
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.2800p0.3900p
0.2800p
Upcoming Events
SVNS
NEUTRALSolvonis Therapeutics featured in media profile
The biopharmaceutical company's lead programmes for addiction and mental health disorders have been profiled in a media article.
SVNS
NEUTRALSolvonis Therapeutics Announces Positive Pre-Clinical Results for PTSD Candidate
The biopharmaceutical company reports positive pre-clinical results for its PTSD drug candidate, advancing three high-performing compounds to in vivo studies.
SVNS
GOODSolvonis Therapeutics Initiates Translational Bridging Studies for SVN-002 AUD Treatment
The biopharmaceutical company has initiated key translational studies to support the advancement of its esketamine oral thin film candidate SVN-002 towards a planned Phase 2b trial in the US for the treatment of Alcohol Use Disorder.
SVNS
VERY BADSolvonis Therapeutics Announces Heavily Discounted Equity Raise
The specialty industrial machinery company has announced a heavily discounted equity raise, raising concerns about its financial health and future prospects.
SVNS
NEUTRALSolvonis Chair to Speak at Lucid Capital Markets Event
The biopharmaceutical company's chairman will participate in a panel discussion at an exclusive investor event hosted by Lucid Capital Markets.
SVNS
GOODSolvonis Therapeutics Raises £1m to Accelerate AI Drug Discovery
The biopharmaceutical company has raised £1 million through a direct subscription to accelerate its AI-supported drug discovery programme, focusing on major depressive disorder and stimulant use disorder.
SVNS
NEUTRALSolvonis Therapeutics Announces Director Dealings
The specialty industrial machinery company has announced changes to its major shareholdings.
SVNS
NEUTRALSolvonis Therapeutics Provides AGM Update
The biopharmaceutical company provides an update on its recent Annual General Meeting, highlighting shareholder support and the company's strategic positioning following a key acquisition.
SVNS
NEUTRALSolvonis Therapeutics Announces Director Shareholding Change
The specialty industrial machinery company has announced a change in director shareholdings.